Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome
Yazarlar (9)
Bülent Behlül Altunkeser Selçuk Üniversitesi, Türkiye
Abdullah Tunçez Selçuk Üniversitesi, Türkiye
Bahadır Öztürk Selçuk Üniversitesi, Türkiye
Hüseyin Tezcan Selçuk Üniversitesi, Türkiye
Doç. Dr. Muhammet Salih ATEŞ Selçuk Üniversitesi, Türkiye
Canan Yılmaz Selcuk University, Türkiye
Muhammed Ulvi Yalçın Selçuk Üniversitesi, Türkiye
Nazif Aygül Selçuk Üniversitesi, Türkiye
Kenan Demir Selçuk Üniversitesi, Türkiye
| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | CORONARY ARTERY DISEASE (Q4) | ||
| Dergi ISSN | 0954-6928 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 06-2019 |
| Cilt / Sayı / Sayfa | 30 / 4 / 285–290 | DOI | 10.1097/MCA.0000000000000715 |
| Makale Linki | https://journals.lww.com/00019501-201906000-00007 | ||
| Özet |
| Aim Current guidelines recommend administration of high-dose statins in acute coronary syndrome (ACS). It has been reported that statins upregulate proprotein convertase subtilisin kexin 9 (PCSK9) mRNA expression and increase circulating PCSK9 levels. We aimed to compare the effects of high-dose atorvastatin and rosuvastatin on serum oxidized low-density lipoprotein (oxidized-LDL) and PCSK9 levels in statin-naive patients with ACS. Patients and methods One hundred and six patients with ACS were enrolled in this study. The patients were assigned randomly to receive atorvastatin (80 mg/day) or rosuvastatin (40 mg/day) by using a ratio of 1 : 1 in randomization. The levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol, LDL-cholesterol, oxidized-LDL, and PCSK9 were compared between groups after a 4-week treatment. Results Our study population included 53 patients in the atorvastatin group (age: 58.13 +/- 11.30 years, 11.32% female) and 53 patients in the rosuvastatin group (age: 59.08 +/- 12.44 years, 15.09% female). In both groups, lipid parameters, oxidized-LDL, and PCSK9 values changed significantly according to the baseline following treatment. High-dose atorvastatin and rosuvastatin induced similar decreases in LDL-cholesterol, oxidized-LDL, and triglyceride levels and similarly increased in high-density lipoprotein cholesterol and PCSK9 levels (P>0.05). Conclusion We showed that atorvastatin and rosuvastatin treatment regimens have comparable effects on lipid parameters and PCSK9 levels in ACS patients. |
| Anahtar Kelimeler |
| acute coronary sydrome | oxidized low-density lipoprotein | proprotein convertase subtilisin kexin 9 |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| WoS | 7 |
| Google Scholar | 14 |